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Abstract
Background: Anophthalmia/microphthalmia (A/M) is caused by mutations in several different transcription factors,
but mutations in each causative gene are relatively rare, emphasizing the need for a testing approach that screens
multiple genes simultaneously. We used next-generation sequencing to screen 15 A/M patients for mutations in 9
pathogenic genes to evaluate this technology for screening in A/M.
Methods: We used a pooled sequencing design, together with custom single nucleotide polymorphism (SNP)
calling software. We verified predicted sequence alterations using Sanger sequencing.
Results: We verified three mutations - c.542delC in SOX2, resulting in p.Pro181Argfs*22, p.Glu105X in OTX2 and p.
Cys240X in FOXE3. We found several novel sequence alterations and SNPs that were likely to be non-pathogenic -
p.Glu42Lys in CRYBA4, p.Val201Met in FOXE3 and p.Asp291Asn in VSX2. Our analysis methodology gave one false
positive result comprising a mutation in PAX6 (c.1268A > T, predicting p.X423LeuextX*15) that was not verified by
Sanger sequencing. We also failed to detect one 20 base pair (bp) deletion and one 3 bp duplication in SOX2.
Conclusions: Our results demonstrated the power of next-generation sequencing with pooled sample groups for
the rapid screening of candidate genes for A/M as we were correctly able to identify disease-causing mutations.
However, next-generation sequencing was less useful for small, intragenic deletions and duplications. We did not
find mutations in 10/15 patients and conclude that there is a need for further gene discovery in A/M.
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Background
Anophthalmia is found in 1 in 5,000 to 10,000 indivi-
duals and is a devastating birth defect because of severe
visual impairment [1]. Genetic testing to identify the
cause of anophthalmia and/or microphthalmia (A/M) is
frequently requested. The transcription factor SOX2 is
mutated in 10-20% of patients with bilateral A/M and
genomic sequencing and deletion analysis of this gene is
the first test to determine the cause of severe bilateral
A / M[ 2 , 3 ] .H o w e v e r ,t h er e m a i n i n gp a t h o g e n i cg e n e s
implicated in A/M, such as OTX2 or GDF6, are each
mutated in a small percentage of patients and more
than 60% of patients with A/M do not receive a molecu-
lar diagnosis after currently available clinical genetic
testing (Table 1) [4-16]. In addition, screening of all of
the known A/M genes is rarely completed on a clinical
basis because there is no currently available panel that
covers all of the known genes.
Next-generation sequencing is a recently developed,
massively parallel, large-scale sequencing technology
that has been used for rapid gene cloning and mutation
detection [16]. Next-generation sequencing with exome
selection was used to identify the causative genes for
Miller syndrome and Kabuki syndrome and has identi-
fied mutations in genes for congenital chloride diarrhea
and Fowler syndrome [17-20]. Next-generation sequen-
cing has primarily been applied to Mendelian disorders
in order to simplify analysis and few birth defects or
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technology to screen known candidate genes in 15
patients with A/M in a pilot study to determine the effi-
cacy of next-generation sequencing for the rapid screen-
ing of multiple genes in patient cohorts with birth
defects.
Methods
Written informed consent and genomic DNA samples
were obtained from 15 patients with A/M (Table 2)
under an approved protocol for the Anophthalmia/
Microphthalmia Registry and gene-screening project
(Institutional Review Board, Albert Einstein Medical
Center). This research adhered to the tenets of the
Declaration of Helsinki.
We divided the 15 patients into two separate groups
(Table 2) for sequencing in individual lanes of a flow
cell - ANOP1 (8 patients) and ANOP2 (7 patients). The
patient samples in each group were pooled without bar-
coding. For ANOP1, we sequenced 9 known A/M genes
(FOXE3, SIX3, SOX2, PAX2, PAX6, BMP4, OTX2, VSX2,
and CRYBA4; gene order dictated by chromosome loca-
tion). Our positive control was patient 09-122, who was
known to have a SOX2 mutation, c.542delC, predicting
p.Pro181Argfs*22. For ANOP2, we added GDF6 so that
10 known A/M genes (FOXE3, SIX3, SOX2, GDF6,
PAX2, PAX6, BMP4, OTX2, VSX2,a n dCRYBA4)w e r e
sequenced. Our positive control was patient 792-531,
with a SOX2 sequence alteration, c.67-69dupGGC,
resulting in the insertion of an additional glycine residue
to the protein.
Primers for amplification of the coding regions were
designed with Primer3 http://frodo.wi.mit.edu/primer3/
based on reference sequences from Entrez Gene http://
www.ncbi.nlm.nih.gov/gene. The primers used are pro-
vided in Additional File 1, Table S1. Polymerase chain
reaction (PCR) products for each patient were pooled
after estimating concentrations on an ethidium bro-
mide-stained agarose gel and correlating with the size of
the amplicon to obtain equal representation of all ampli-
cons in the final mixture. Pooled DNA reactions were
column purified (Qiagen, Valencia, CA) and libraries
were prepared for sequencing on the Illumina genome
analyzer (GA) platform (Illumina, San Diego, CA). We
used 32-bp, paired-end reads and the standard sequen-
cing primer (Illumina, San Diego, CA). After library
construction, quality was checked using a DNA chip
(2100 Bioanalyzer; Agilent Technologies, Santa Clara,
CA). The libraries were sequenced at the Vincent J.
Coates Genomics Sequencing Laboratory, California
Institute for Quantitative Biosciences http://qb3.berke-
ley.edu/gsl/Home.html. Image analysis and base calling
was performed by Illumina pipeline version 1.4 with
default parameters (Illumina, San Diego, CA). We first
aligned the raw Solexa reads to the reference genome
(build 36.3) with MAQ and then rescaled the initial
Solexa quality scores to FASTQ format as described in
the MAQ’s manual http://maq.sourceforge.net/maq-
Table 1 Known Anophthalmia/Microphthalmia Genes Investigated by Next-Generation Sequencing
Gene Chromosome location NCBI Reference
Sequence (hg19)
mRNA
Exon
count
Coding exon
count
Estimated
Mutation
Frequency
4,5
Inheritance
pattern
Reference
SOX2 chr3:182912416-
182914917
NM_003106.2 1 1 10-20% Autosomal
dominant
6,7
GDF6 chr8:97,223,734-
97,242,196
NM_001001557.2 3 3 8% Autosomal
dominant
5
OTX2 chr14:56337178-
56346937
NM_021728.2 5 3 3.3% Autosomal
dominant
8
VSX2 chr14:73775928-
73799194
NM_182894.2 5 5 2% Autosomal
dominant
9
FOXE3 chr1:47654331-47656311 NM_012186.2 1 1 Rare Autosomal
recessive/
Autosomal
dominant
10
CRYBA4 chr22:25347928-
25356636
NM_001886.2 6 5 Rare Autosomal
Dominant
11
PAX2 chr10:102495458-
102579688
NM_003990.3 11 11 Rare Autosomal
dominant
12
PAX6 chr11:31762916-
31796085
NM_000280.3 13 10 Rare Autosomal
dominant
13
SIX3 chr2:45022541-45025894 NM_005413.3 2 2 Rare Autosomal
dominant
14
BMP4 chr14:53486205-
53491020
NM_001202.3 4 2 Rare Autosomal
dominant
15
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meters - albeit with a larger outer distance for a correct
read pair (-a 500) and a larger threshold on the sum of
mismatching base qualities (-e100). We then used the
Genome Analysis Toolkit to further rescale the quality
scores of the aligned reads to match empirical error
rates as described previously (1000 Genome Project
Consortium, 2010) [22]. Briefly, bases were binned by
original quality score, machine cycle, and neighboring
nucleotide; empirical errors rates were assessed for each
bin at non-dbSNP sites; and recalibrated quality scores
were assigned to each bin to match the empirical error
rate. We then ignored bases with recalibrated quality
scores below 20 (Q20) and measured coverage at each
targeted base to assess experimental completeness.
We then called variants using Syzygy (J. Flannick,
manuscript in preparation), a previously described soft-
ware package designed to call variants in non-indexed
pooled groups of samples [23]. Briefly, the goal of
variant calling is to distinguish true variation from
sequencing errors. This task is harder in the pooled set-
ting than in the single sample setting because the fre-
quency of a single minor allele in the pool (1/2N, where
N is the number of samples in the pool) can approach
the raw error rate of Solexa reads (1% at Q20 bases). To
call a variant at a genomic position, Syzygy compares
the likelihood that a variant exists in the pool to the
likelihood that all non-reference sequence bases at the
position are due to sequencing errors. At positions
where the log of the likelihood ratio is above 3, Syzygy
calls a variant and then uses an expectation-maximiza-
tion (EM) algorithm to determine the number of sam-
ples in the pool who carry the variant. Syzygy further
declares as high-confidence variants that (1) have statis-
tically indistinguishable numbers of non-reference bases
on reads from the forward (+) and reverse (-) strands of
the genome; (2) have positive log-likelihood ratios based
solely on reads from the forward strand and also based
Table 2 Summary of Ocular Phenotypes and Next-Generation Sequencing Results in Two Patient Groups
Patient Right and Left Eye Findings Additional features Next generation coding sequence
alterations verified by Sanger sequencing in
this study
ANOP1
792-
505
Anophthalmia - -
792-
508
Anophthalmia Feeding disorder c.313C > T ® p.Glu105X in OTX2
792-
526
Anophthalmia Learning disabilities -
792-
539
Anophthalmia Asperger syndrome -
792-
542
Microphthalmia, coloboma, cyst - c.24C > G ® p.Leu8Leu in GDF6
c.618C > G (Hz) ® p.Ala206Ala in FOXE3
792-
570
Anophthalmia/Microphthalmia, microcornea, lens
opacification
- c.601 G > A ® p.Val201Met in FOXE3
792-
601
Microphthalmia, chorioretinal colobomas Hydrocele -
09-122 Anophthalmia - c.542delC ® p.Pro181Argfs*22 in SOX2
ANOP2
792-
056A
Microphthalmia Pervasive developmental disorder -
792-
518
Microphthalmia Hamartoma tuber cinereum c.124 G > A ® p.Glu42Lys in CRYBA4
[c.70del20 in SOX2]
792-
530
Anophthalmia Learning disabilities, Arnold-Chiari
malformation
-
792-
531
Anophthalmia - c.871 G > A ® p.Asp291Asn in VSX2;
[c.67-69dupGGC in SOX2]
792-
548
Microphthalmia - -
792-
563
Microphthalmia Arnold-Chiari malformation c.720C > A (Hz) ® p.Cys240X in FOXE3
792-
572
Anophthalmia Learning disabilities, autistic behavior c.520 G > A (Hz) ® p.Ala174Thr in FOXE3
Coding sequence variants only are included and mutations are highlighted in bold; (Hz) = Homozygous sequence alteration; the remainder of the sequence
alterations were heterozygous.
Lopez Jimenez et al. BMC Medical Genetics 2011, 12:172
http://www.biomedcentral.com/1471-2350/12/172
Page 3 of 8solely on reads from the reverse strand; and (3) do not
occur adjacent to another variant. We used these high
confidence variants as our final call set, with all coding
variants having likelihood ratio > 3.0 on both forward
and reverse strands.
Coding sequence variants were verified by Sanger
sequencing on genomic DNA or whole-genome-ampli-
fied (WGA) DNA (GenomePlex Whole Genome Ampli-
fication kit; Sigma, St Louis, MO). Sequence variants
found in WGA samples were confirmed in genomic
DNA to exclude the small possibility of errors induced
by the WGA.
Results
In ANOP1, 13 coding sequence variants were predicted
by our method of analysis, 8 of which were listed in the
Database of Single Nucleotide Polymorphisms (dbSNP;
Table 3). The five predicted sequence variants not in
dbSNP were verified by Sanger sequencing as follows:
We detected the SOX2 mutation, c.542delC, predicting
p.Pro181Argfs*22, in patient 09-122, our positive control
(Figure 1A). However, this mutation was predicted as a
deletion at position c.539 (c.539A > D), 3 bp prior to
the location of the actual mutation. c.542delC was not
included in a comprehensive recent review of SOX2
mutations [7], but the sequence alteration can be pre-
sumed to be disease-causing because of likely loss of
function, although the deletion occurs after the high
mobility group (HMG) domain in the protein. Parental
studies were not performed.
We predicted c.313C > T in OTX2, causing p.Gln105X
and a premature stop codon just after the homeodomain
of the 297 amino acid OTX2 protein (Table 3). This
mutation was verified with Sanger sequencing in 792-
508 (Figure 1B). This mutation is consistent with the
loss of function mutations observed in OTX2 in A/M
patients [8]. Testing of the healthy parents of this child
did not show the same mutation [8].
We verified c.601 G > A, predicting p.Val201Met in
FOXE3, in patient 792-570 (Additional File 2 Figure
Table 3 Coding Sequence Variants Predicted by Syzygy and Verified by Sanger Sequencing in the ANOP1 and ANOP2
Libraries
Gene Position (hg18) Nucleotide
Alteration
a
Predicted Effect on
Protein
dbSNP/1000 Genomes Sanger Sequencing Het./
Homo.
b
Interpretation
ANOP1
FOXE3 chr1:47655084 c.510C > T p.Ala170Ala rs34082359 Yes; verified Het. SNP
FOXE3 chr1:47655175 c.601 G > A p.Val201Met - Yes; verified
10 Het. SNP
FOXE3 chr1:47655192 c.618C > G p.Ala206Ala - Yes; verified
10 Homo. SNP
SIX3 chr2:45022837 c.90 G > T p.Ala30Ala rs78018362 Not done Het. SNP
SIX3 chr2:45025346 c.942A > G p.Ala314Ala rs62840660 Not done Het. SNP
SOX2 chr3:182913381 c.539A > D
c Predicted FS
d - Yes; c.542delC verified Het. Mutation
GDF6 chr8:97242073 c.24C > G p.Leu8Leu - Yes, verified Het. Unknown
PAX2 chr10:102558862 c.867C > T p.Asn289Asn rs1800897 Not done Het. SNP
PAX2 chr10:102558973 c.978A > C p.Pro326Pro rs1800898 Not done Het. SNP
BMP4 chr14:53487272 c.455T > C p.Val152Ala rs17563 Not done Het. SNP
OTX2 chr14:56338763 c.313C > T p.Glu105X - Yes; verified
8 Het. Mutation
VSX2 chr14:73781636 c.471C > T p.Ser157Ser rs35435463 Not done Het. SNP
CRYBA4 chr22:25351457 c.171C > T p.Phe57Phe rs5761637 Not done Het. SNP
ANOP2
FOXE3 chr1:47655084 c.510C > T p.Ala170Ala rs34082359 Yes; verified Het. SNP
FOXE3 chr1:47655294 c.720C > A p.Cys240X - YES; verified
10 Homo. Mutation
SIX3 chr2:45023323 c.576C > T p.Arg192Arg rs182881 Not done Het. SNP
PAX2 chr10:102558862 c.867C > T p.Asn289Asn rs1800897 Not done Het. SNP
PAX2 chr10:102558973 c.978A > C p.Pro326Pro rs1800898 Not done Het. SNP
PAX6 chr11:31768060 c.1268A > T p.X423Leu
extX*15
- YES; not verified
24 Het. Mutation
BMP4 chr14:53487272 c.455T > C p.Val152Ala rs17563 Not done Het. SNP
VSX2 chr14:73781636 c.471C > T p.Ser157Ser rs35435463 Not done Het. SNP
VSX2 chr14:73797160 c.871 G > A p.Asp291Asn rs75395981 YES; verified Het. SNP
CRYBA4 chr22:25349282 c.124 G > A p.Glu42Lys - YES; verified Het. Unknown
CRYBA4 chr22:25351457 c.171T > C p.Phe57Phe rs5761637 Not done Het. SNP
aNucleotide numbering is according to dbSNP (Database of Single Nucleotide Polymorphisms; http://www.ncbi.nlm.nih.gov/projects/SNP/). Het./Homo.
b =
heterozygous or homozygous sequence alteration; D
c = predicted deletion; FS
d = frameshift.
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S1Aii). This SNP has not yet been included in public
databases, but has previously been reported in both A/
M patients and normal controls and is likely to be a
polymorphism [10]. We verified c.618C > G, a synon-
ymous alteration resulting in p.Ala206Ala in FOXE3,i n
patient 792-542, who was homozygous for this SNP
(Additional File 2, Figure S1B). The SNP has previously
been described in both A/M patients and controls [10].
Finally, we verified c.24C > G, predicting a synonymous
alteration, p.Leu8Leu in GDF6, in patient 792-542
(Additional File 2, Figure S1C). This novel, synonymous
sequence alteration was not predicted to have a signifi-
cant effect on splicing (Automated Splice Site Analysis;
https://splice.uwo.ca). Its significance is therefore
uncertain, although it is most likely to be a SNP, as it is
present in a low frequency (1/10,755 alleles in the Cau-
casian and African-American populations) in the Exome
Variant Server http://evs.gs.washington.edu/EVS/. We
were unable to obtain parental samples.
In ANOP2, 12 coding sequence variants were pre-
dicted, of which 9 had been documented in dbSNP or
the 1000 genomes database (http://www.1000genomes.
org/; Table 3). From the 3 sequence alterations that
were not in public databases, we verified c.720C > A,
predicting p.Cys240X in FOXE3 by Sanger sequencing
in patient 792-563 (Figure 1C). The patient was homo-
zygous for this published mutation, consistent with the
autosomal recessive inheritance described with FOXE3
mutations [10].
Figure 1 Mutations in the coding sequence of anophthalmia genes in ANOP1 and ANOP2 patients. Figure 1A. Chromatogram showing
c.542delC in SOX2 in patient 09-122, predicted as c.539A > D. Figure 1B. Chromatogram showing c.313C > T in OTX2, predicting p.Gln105X in
patient 792-508. Figure 1C. Chromatogram showing c. 720C > A in FOXE3, predicting p.Cys240X in patient 792-563.
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VSX2 in patient 792-531 (Additional File 2, Figure S1D).
This sequence variant is a SNP present in the 1000 gen-
omes database and in dbSNP. We also verified c.124 G
> A, resulting in p.Glu42Lys in CRYBA4, in patient 792-
518 (Additional File 1, Figure S1E). Sequencing of 90
control chromosomes was normal for this sequence var-
iant (data not shown) and Polyphen-2 http://genetics.
bwh.harvard.edu/pph2/ predicted that the alteration was
‘possibly damaging’, although the position-specific inde-
pendent counts (PSIC) score was low at 0.438. Parental
samples were unavailable and the significance of this
sequence variant is not known, although it is likely to
be a SNP as the same patient has a pathogenic deletion
in SOX2. Finally, we predicted c.1268A > T, resulting in
p.X423LeuextX*15, a previously described ‘run-through’
mutation in PAX6 [24]. However, we did not verify this
sequence change using a forward primer (Additional file
3, Figure S2) and the polyA tail from the PAX6 gene
prevented sequencing in the reverse direction. This was
the only predicted missense alteration that we were
unable to confirm.
In ANOP2, patient 792-531 was known to have a
three base pair insertion in SOX2, c.67-69dupGGC, pre-
dicting the insertion of an additional glycine residue at
residue 24 after a stretch of five glycine residues at
amino acids 19-23 in the wildtype protein (data not
shown). Patient 792-518 was also found to have the
common SOX2 deletion, c.70del20, resulting in p.
Asn24fs*88 and premature protein truncation during the
course of this work [9]. Neither of these mutations was
predicted when we used high likelihood scores in both
the forward and the reverse strands at the same base for
mutation prediction (data not shown). This methodol-
ogy would not have detected larger deletions or inser-
tions, as one strand could still contain normal sequence
at the base involved in the mutation, depending on the
size of the abnormality. We therefore re-checked all of
the predictions for deletions and insertions that had a
likelihood ratio > 3.0 in either the forward or the reverse
strand for SOX2 and found that both an insertion and
deletion were predicted at nucleotide c.57 G (data not
shown). Although this prediction was not precisely at
the position of c.67-69dupGGC or c.70del20, Sanger
sequencing of this region in the ANOP2 patients would
have lead to the verification of the duplication in patient
792-531 and the deletion in patient 792-518 (data not
shown). It should also be noted that we used short
reads and that a 20 bp deletion in the read size may
result in insufficient homology for a read to be accu-
rately mapped to the reference genome. We conclude
that our analysis was highly effective for the detection of
missense alterations, but less efficient for deletions and
duplications, particularly those of a larger size. Our
analysis did not predict any large copy number variants
(data not shown).
Coverage for the ANOP1 library was high, with 100%
of coding sequence of the 9 genes at > 160X coverage (i.
e. > 20X for 8 samples) except for exon 6 of PAX2,
which was not covered by the library (Additional file 1,
Table S2). For ANOP2, there was 100% coverage for the
coding exons of 8 genes at > 140X (i.e. > 20X for 7 sam-
ples). Exon 6 of PAX2 was not covered and FOXE3
(78.7% > 140X coverage) and SIX3 (96.9% > 140X cover-
age; Additional file 1, Table S2) had reduced coverage
for some regions in the ANOP2 library. It is unclear if
the reduced coverage has resulted in false negative
results. We did detect homozygosity for c.520 G > A,
predicting p.Ala174Thr in FOXE3, by Sanger sequencing
in patient 792-572 whilst sequencing to verify c.720C >
Ai nFOXE3 (Table 2; data not shown). The c.520 G >
A sequence alteration was novel and was not predicted
with the high threshold parameters used, but was
deemed likely to be benign by Polyphen-2, with a PSIC
score of 0.025 (data not shown).
Discussion
We were able to use next-generation sequencing to
screen multiple pathogenic genes efficiently in a cohort
of 15 A/M patients and were able to identify disease-
causing mutations in three patients: c.542delC, predict-
ing p.Pro181Argfs*22 in SOX2 (positive control), c.313C
>Ti nOTX2, predicting p.Gln105X, and c.720C > A,
predicting p.Cys240X, in FOXE3. All of these alterations
are consistent with loss of function and are considered
to be pathogenic. We retrospectively identified a known
duplication and deletion in SOX2 in two further patients
using our analysis method with altered parameters that
required a high likelihood score in one strand only (data
not shown), but the basepair at which the sequence
alteration was predicted was not an exact match to the
aberrations found by Sanger sequencing. We did not
find mutations in the other 10 patients, although our
screening was incomplete in that the GDF6 gene was
not covered in the ANOP1 library and neither library
covered RAX. However, our studies emphasize the
genetic heterogeneity of A/M, the rarity of mutations in
some of the known pathogenic genes and the need for
further gene discovery.
We encountered several difficulties with our next-gen-
eration sequencing methodology. We chose not to bar-
code our samples to simplify library preparation, but
our lack of bar-coding to distinguish between different
samples increased the number of patients in whom San-
ger sequencing was needed. Using bar-coding would
have simplified our analysis. We identified relatively few
novel coding variants that required Sanger sequencing
using Syzygy as our analysis tool, which was a strength
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diction of previously reported SNPs as likely to be cor-
rect. The error rate of massively parallel sequencing has
been estimated to be high, at 0.5% per base call [25]. A
high false positive rate is more likely when pooling sam-
ples and with low expected frequencies of variant detec-
tion, and less likely with increased depth of coverage
and paired-end reads [25]. In a recent study, only 74 out
of 114 predicted mutations or sequence variants (65%)
were confirmed with Sanger sequencing [25]. In our
much smaller study, we confirmed 8/9 predicted var-
iants (87.5%).
One of the predicted mutations from our next-genera-
tion sequencing, c.1268A > T, resulting in p.
X423LeuextX*15 in PAX6 is especially noteworthy. This
mutation has previously been described in four patients
with aniridia, without mention of A/M (PAX6 home-
page; Leiden Open Variation Database; http://lsdb.hgu.
mrc.ac.uk/home.php?select_db=PAX6). The mutation
results in an alteration to the normal stop codon, result-
ing in ‘run-through’ and a later stop after a further 15
amino acids. It was surprising to us that a mutation for
an eye malformation, albeit one distinct from A/M,
would be predicted but not verified despite high cover-
age in that region and the possibility of a low level of
mosaicism not detectable by Sanger sequencing cannot
be excluded.
Conclusion
We used next-generation sequencing with a pooled
approach to sequence 9 known causative genes in 15 A/
M patients. We were successful in identifying three
mutations - c.542delC in SOX2,r e s u l t i n gi np .
Pro181Argfs*22, p.Glu105X in OTX2 and p.Cys240X in
FOXE3. Our analysis methodology resulted in one false
positive PAX6 mutation that was not verified by Sanger
sequencing; we were also unable to detect a small dele-
tion of 20 bp and a duplication of 3 bp, both in SOX2.
Next-generation sequencing with pooled samples
enabled rapid screening of candidate genes for A/M and
efficient detection of missense mutations; however, we
were less successful in finding small intragenic deletions
and duplications.
Additional material
Additional file 1: Table S1. Amplified Fragments and Primers for
Anophthalmia/Microphthalmia Genes. Table S2. Summary of Coverage for
Coding Sequence of Anophthalmia/Microphthalmia Genes in ANOP1 and
ANOP2 Libraries
Additional file 2: Figure S1. Single Nucleotide Polymorphisms (SNPs)
and Sequence Alterations of Uncertain Significance in Anophthalmia
Genes in the ANOP1 and ANOP2 Libraries. Figure S1A. Chromatogram
showing c.601 G > A, predicting p.Val201Met in FOXE3 in (i) patient, 792-
570, and (ii) parent, 792-569. Figure S1B. Chromatogram showing c.618C
> G, predicting p.Ala206Ala, in FOXE3 in patient 792-542. Figure S1C.
Chromatogram showing c.24C > G, predicting p.Leu8Leu, in GDF6 in
patient 792-542. Figure S1D. Chromatogram showing c.871 G > A,
predicting p.Asp291Asn, in VSX2 in patient 792-531. Figure S1E.
Chromatogram showing c.124 G > A, predicting p.Glu42Lys, in CRYBA4,
in patient 792-518.
Additional file 3: Figure S2. Predicted coding sequence variants in
ANOP1 and ANOP2 patients that were not verified by Sanger
sequencing. Figure S2. Chromatograms showing normal sequence at
c.1268A > T, predicting p.X423LeuextX*15 in PAX6, in patients from
ANOP2.
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